VolitionRx Ltd., a multi-national epigenetics company, announced it is preparing a reimbursement submission for its Nu.Q Cancer assays to government agencies in France. The submission will be actively supported by Hospices Civils de Lyon, France's second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL.
HCL researchers stated the Nu.Q Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following completion of the reimbursement and certification processes. Data generated through collaboration with Volition indicate that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis can provide information related to survival and disease progression. This approach may also help identify patients who could benefit from curative care.
Volition said the reimbursement submission is expected to be filed under France's "Innovative Procedures Outside the Nomenclature" framework, which allows early reimbursement support for innovative medical procedures. The company noted that reimbursement would represent a major milestone toward routine clinical use of Nu.Q Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.
The development has significant implications for cancer diagnostics and patient care. If successful, the reimbursement approval could establish a precedent for integrating epigenetic blood tests into standard clinical pathways, potentially improving early detection and personalized treatment strategies for lung cancer patients. This could lead to better survival outcomes and more efficient allocation of healthcare resources by identifying patients most likely to benefit from specific interventions.
For the medical diagnostics industry, Volition's progress in France demonstrates the growing acceptance of epigenetic approaches in mainstream oncology. The collaboration with a major university hospital system like Hospices Civils de Lyon adds credibility to the technology and may accelerate adoption in other European markets. The company's focus on simple, cost-effective blood tests aligns with broader healthcare trends toward minimally invasive diagnostics that can be widely implemented.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
For more information about the company, visit https://www.Volition.com. The original press release can be viewed at https://ibn.fm/qxNIy.
